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Simple Summary: The Dead-End (DND1) protein can interact with different messenger RNAs
(mRNAs) in the cell. It uses multiple mechanisms to regulate expression of proteins from their
cognate mRNAs. High levels of DND1 are found in the progenitor cells that develop into the egg
and sperm. Here we review how and why defects in DND1 cause tumors in the testes and ovaries of
vertebrates. Unexpectedly, some recent reports indicate that DND1 may also participate in human
cancer development in cells other than those of the testes and ovaries. The goal of this review is
to summarize the literature on the role of DND1 in cancers to obtain perspective regarding future
scientific endeavors on DND1 function.
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Abstract: The Ter mutation in Dead-End 1 (Dnd1), Dnd1Ter , which leads to a premature stop codon,
has been determined to be the cause for primordial germ cell deficiency, accompanied with a high
incidence of congenital testicular germ cell tumors (TGCTs) or teratomas in the 129/Sv-Ter mice.
As an RNA-binding protein, DND1 can bind the 30 -untranslated region (30 -UTR) of mRNAs and
function in translational regulation. DND1 can block microRNA (miRNA) access to the 30 -UTR of
target mRNAs, thus inhibiting miRNA-mediated mRNA degradation and up-regulating translation
or can also function to degrade or repress mRNAs. Other mechanisms of DND1 activity include
promoting translation initiation and modifying target protein activity. Although Dnd1Ter mutation
causes spontaneous TGCT only in male 129 mice, it can also cause ovarian teratomas in mice when
combined with other genetic defects or cause germ cell teratomas in both genders in the WKY/Ztm
rat strain. Furthermore, studies on human cell lines, patient cancer tissues, and the use of human
cancer genome analysis indicate that DND1 may possess either tumor-suppressive or -promoting
functions in a variety of somatic cancers. Here we review the involvement of DND1 in cancers,
including what appears to be its emerging role in somatic cancers.
Keywords: DND1; germ cell; teratomas; somatic cancers; translation regulator
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1. Introduction
The story of Dead-End 1 (DND1) in cancer of mouse germ cells can be traced back
almost half a century. A new spontaneously arising mutation led to generation of the new
inbred subline of mice (129/Sv-Ter) that exhibited primordial germ cell (PGC) deficiency,
accompanied with a high incidence of congenital testicular germ cell tumors (TGCTs) or
teratomas [1–3]. These recessive phenotypes mapped to mouse chromosome 18, or the Ter
locus [4,5]. In 2005, twenty years after the 129/Sv-Ter mouse line was isolated, positional
cloning of Ter identified the genetic defect to a mutation in Dead-End 1, a mouse ortholog
of the zebrafish dead-end gene required for PGC migration and survival [6]. Mouse Dnd1
contains four exons. Ter is due to a single nucleotide substitution occurring spontaneously
in exon 3 of Dnd1, which transforms the arginine residue at amino acid (aa) 190 into a
premature stop codon, thus causing either truncation or loss of DND1 expression (Figure 1).
This mutation results in the phenotypes of PGC loss, male and female sterility, and the
high incidence of TGCT in males of the 129/Sv mice.
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2. Molecular Mechanisms of DND1 Function
2.1. mRNA Stabilization
Several studies have demonstrated that DND1 can bind specific mRNAs and block
microRNA (miRNA) access from the 30 -untranslated region (30 -UTR) of target mRNAs and
inhibit miRNA-mediated mRNA degradation, thus up-regulating translation (Figure 2a).
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DND1 function of blocking miRNA access is also subject to negative regulation or
DND1 itself is subject to miRNA regulation. For example, Xenopus dnd1 mRNA can
be cleared by miR-18 in the soma and specifically protected from degradation in germ
line of Xenopus embryos via Elr-type proteins [24]. Another example in squamous cell
carcinoma cell lines demonstrated that miR-24 down-regulates DND1 [13]. The DNA
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cytosine deaminase, apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like
3 (APOBEC3), was found to interact with DND1 [25] and counteract DND1 function by
restoring the suppressive activity of miRNA on p27, LATS2 and CX43 mRNAs [26].
A recent study dissected the individual functions of the two RRMs of Dnd1 in regulating nanos1 translation in Xenopus germline [8]. The N-terminal RRM1 is critical for
interaction with mRNA targets [7,8,10]. The RRM2 possesses ATP-dependent helicase
activity [8,27] required to resolve the secondary structure of bound mRNAs to promote
translation [8]. The above-mentioned HRAAAMA motif is presumably part of the putative
ATPase domain. Furthermore, CRISPR-Cas9-mediated base-editing generated mutations
of four aas in RRM1 of mouse DND1 (E59, V60, P76 and G82), which functions in mRNA
binding, depleted PGCs in mouse embryos, indicating the essential role of these RRM1 aas
for DND1 function during PGC development [28].
2.2. mRNA Repression or Degradation
Other studies show that DND1 can also function as a translation suppressor [9,10,29].
It binds a UU(A/U) trinucleotide motif predominantly in the 30 -UTR regions of mRNA
and in addition recruits the CCR4-NOT deadenylase complex, to degrade target mRNAs
(Figure 2b). The mRNA targets of DND1 destabilized by CCR4-CNOT include genes
associated with apoptosis, inflammation, and pathways that regulate stem cells, such
as of the TGF, WNT and PI3K-AKT signaling pathways [10]. In germ cells, DND1 has
also been shown to partner with NANOS2 [9,30,31], an evolutionarily conserved RNAbinding protein specifically involved in germ cell development, and then interact with
CCR4-NOT. DND1 is required for loading unique RNAs into the Nanos2-CCR4-NOT
complex [9], likely accounting for the synergistic increase of incidence of TGCT in double
mutants for DND1 and NANOS2 [31]. On the other hand, Dnd1 has also been shown to
bind mRNA and repress their translation without affecting their stability during zebrafish
embryogenesis [29]. Further studies to elucidate the exact cellular and physiological context
of these mechanisms are needed.
DND1 has a long list of target mRNAs [10,23,32–34], which is expected to grow
longer. In germ cells, DND1 down-regulates many genes associated with pluripotency
and active cell cycle (e.g., Rheb, Rhob, Ccne1, and Trp53 etc.) whereas it up-regulates
chromatin regulator genes (e.g., Kat7, Rbbp5, Kdm5a, and Setdb1 etc.) [34], suggesting that
post-transcriptional up- or down-regulation may exist concurrently in cells and could be
mRNA target-specific.
2.3. Other Molecular Functions of DND1
In addition to overcoming the inhibitory action of miRNA, DND1 can also activate
germline-specific translation through promoting initiation. In Xenopus oocytes, Dnd1 binds
to the mRNA of germline gene nanos1 and interacts with eukaryotic initiation factor 3f
(eIF3f) which is a repressive component in the 43S preinitiation complex [35]. This Dnd1eIF3f interaction counteracts the repressive activity of eIF3f and leads to nanos1 translation.
DND1 was also found to possess a unique function of modifying the activity of target
protein. In mouse embryos, DND1 interacts with the activator protein 1 (AP1) subunit
c-Jun [36]. Co-transfection with Dnd1 and c-Jun plasmids in GC-1 mouse spermatogonia
cells significantly increased the transcriptional activity of AP1.
DND1 has been detected in both the cytoplasm and nucleus [37–39], in line with
the function of DND1 as a post-transcriptional [7,9,10,29] or transcriptional regulator [36].
What determines the multifaceted regulatory roles of DND1 is still unknown. Whether
the different reported functions of DND1 are species-specific also remains to be clarified.
A recent study revealed an interesting 3D domain swapped dimerization of the DND1RRM2 domain [40], which increases surface area for multimeric interactions and may allow
DND1 to exert different functions in different context. Further investigations are warranted
to elucidate the mechanisms and causes underlying the multifaceted roles of DND1.
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3. Dnd1Ter Mutation in Testicular and Ovarian Teratomas
In vertebrates, PGCs segregate from pluripotent epiblast cells and migrate into the
developing gonads, where they specify into either male or female germ cells. In mice, Dnd1
expression is specifically induced in PGC precursors at embryonic day (E) 6.5–6.75 and
maintained until the pre-meiotic spermatogonia stage in adult testes [10]. Immunoblotting
using mouse-specific anti-DND1 antibodies has detected DND1 in the spermatids of adult
mouse testes but not in Sertoli cells [39]. Additionally, examination of The Human Protein
Atlas indicates DND1 mRNA is enriched in spermatogonia and early spermatids (https:
//www.proteinatlas.org/ENSG00000256453-DND1/celltype, accessed on 18 July 2021)
from human testis [41–43].
The Dnd1Ter mutation causes PGC loss in all mouse genetic backgrounds, leading to
infertility in both genders. However, only male Dnd1Ter mice on the 129 strain background
develop the cancerous TGCT. In these mice, some of the remaining PGCs acquire the
intermediate pluripotent status [44] to transform into highly proliferative, undifferentiated
pluripotent embryonal carcinoma (EC) cells. At the time of birth, most EC cells differentiate into random mix of various cells and tissues that compose the teratomas of TGCTs.
Although the incidence of teratomas in wild-type (WT) strain 129/Sv males is 1.4%, the
Dnd1Ter mutation increases teratoma incidence to 17% in heterozygous mutants and 94% in
homozygotes [2]. Thus, Dnd1Ter is a potent modifier of spontaneous TGCT susceptibility
on the 129 strain background.
More strikingly, in the WKY/Ztm rat strain, homozygous mutation in Dnd1 led to
formation of congenital testicular and ovarian teratomas, as well as infertility with complete
penetrance in both genders [11]. The rat Dnd1Ter was determined as a point mutation in
exon 4 of rat Dnd1, which introduces a premature stop codon at aa 289, resulting in a
longer truncated protein compared to the predicted mouse Dnd1Ter mutant (Figure 1).
The HRAAAMA motif is lost in the mouse DND1Ter mutant due to the premature stop
codon at aa 190, but remains intact in rat Ter [14] (Figure 1), which may explain for the
gender difference in Dnd1Ter -related teratocarcinogensis between mouse and rat. A series
of studies from Tokumoto’s lab also point to the role of DND1 in female germ cells. They
determined that the ett1 locus, on mouse chromosome 18 but separate from the Ter locus,
is responsible for experimentally testicular teratoma (ETT) formation induced in 129/Sv
mice when E12.5 fetal testes are transplanted into adult testes [45]. They subsequently
identified a single nucleotide polymorphism that introduces glycine to serine mutation at
aa codon 25 (G25S) in melanocortin 4 receptor (Mc4r) gene within the ett1 locus [46]. In
a very recent report, they showed that the MCR4 G25S homozygotes also caused OTs) in
48.7% of LTXBJ mice. The incidence of OT was further increased to 66.7% when Ter locus
of the 129 strain was introduced in heterozygous to Mc4rG25S/G25S mice [12].
DND1 was found to interact with several pluripotency associated mRNAs, OCT4,
SOX2, LIN28 and BCL2L1, in the germinal vesicle-stage of pig oocytes [47]. In Xenopus
oocytes, Dnd1 was also subject to ubiquitin-independent proteasomal degradation and
translational repression, regulations that prevent premature accumulation of Dnd1 in
oocytes [48]. These reports highlight the role of DND1 and its interactions with specific
genetic susceptibility factors that result in germ cell tumors (TGCTs or OTs) in male and
female animal model systems.
In contrast to its function in mouse TGCT, germline DND1 mutations were shown
unlikely to contribute significantly to human TGCT susceptibility [49,50]. In addition,
DND1 was not detected among the panel of putative prognostic and diagnostic markers of human TGCT tissues identified by proteomic techniques [51], indicating DND1
may not play a significant role in human TGCT. The functional discrepancy between
mouse and human DND1 in TGCT is probably not surprising, considering that even
in mouse, the increase of TGCT incidence by Dnd1Ter is highly dependent on the strain
genetic background [32] and genetic susceptibility factors other than Dnd1Ter can also
increase TGCT occurrence in mouse [45,52,53]. On the other hand, mechanistic studies
indicate a link between DND1 and miRNAs that characterize human TGCTs. For example,
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DND1 was found to interact with LATS2 mRNA to alleviate miR-372-mediated LATS2
suppression [7,32,33]. Furthermore, proteins such as APOBEC3 that interact with DND1
can modulate DND1 function of blocking miR-372 [26]. Significantly, miR-372 belongs
to the miR-371-373 cluster, which is one of the most relevant biomarkers for TGCTs in
patients [54,55]. Thus, further investigation is warranted to elucidate any putative link
between DND1 function and miRNA signatures of human TGCT.
4. The Emerging Role of DND1 in Somatic Cancers
Although in the zebrafish, Dnd1 is exclusively expressed in germ cells, in mammals
it appears that lower levels of DND1 are expressed in a variety of cells and tissue types,
mainly of epithelial or mesenchymal origin. DND1 expression has been reported in
normal human neutrophils, hematopoietic CD34+ progenitor cells [16], rat neural stem
cells, neurons and astrocytes [56] and in breast epithelial cells [17]. Additionally, emerging
evidence indicates a role of DND1 not limited to only in germ cell cancers but also in some
types of somatic cancers [13–19]. Table 1 summarizes the studies of DND1 in different
cancer types. Importantly, these studies on DND1 not only used established cancer cell
lines but used patient derived cancer tissue samples. We discuss below the studies on
DND1 in breast cancer, gastrointestinal (GI) cancers, tongue squamous cell carcinoma
(TSCC) and leukemia.
Table 1. Studies on the role of DND1 in somatic cancers.
Tumor Type

Endogenous DND1 Status in
Human Cell or Tissue Samples

Phenotypes Caused by
Experimental Alteration of DND1

Mechanism of DND1 Function

Reference

Breast cancer

Lower expression of DND1
levels in breast cancer tissue
compared to normal.

Knockdown of DND1 in MCF-7
cells decreased BIM expression
and inhibited apoptosis.

DND1 increases expression
of BIM by blocking miR-221
from BIM-30 UTR.

[17]

Hepatocellular
carcinoma (HCC)

DND1 mRNA and protein
levels significantly decreased
in HCC sphere cells.

DND1 overexpression inhibited
spheroid formation; suppressed
HCC cancer cell stemness; inhibited
epithelial-mesenchymal transition;
increased sensitivity of HCC cells
to sorafenib.

DND1 binds to LATS2 30 -UTR,
elevating LATS2 level and YAP
phosphorylation and retention in
the cytoplasm, therefore diminishing
transcriptional activity of YAP.

[18]

Intestinal polyposis

N/A

Apc+/Min Dnd1+/Ter mice had higher
polyp numbers compared to
Apc+/Min Dnd1+/+ mice.

N/A

[14]

Colorectal cancer (CRC)

DND1 expression significantly
up-regulated in CRC cell lines.

Silencing DND1 reduced SW48 cell
line viability and overexpression of
DND1 promoted cell proliferation.

DND1 is the potential target of
miR-24 in SW48 cells and involved
in miR-24 mediated inhibitory
effects on cell proliferation.

[19]

Tongue squamous cell
carcinoma (TSCC)

Reduced expression of DND1
in TSCC cells and tissues.

DND1 knockdown in TSCC cell lines
enhanced cell proliferation and
reduced apoptosis. Enhanced DND1
expression reduced cell proliferation
and increased apoptosis.

DND1 is a direct target of miR-24.
miR-24 suppressed DND1, leading
to reduced CDKN1B.

[13]

Acute myeloid
leukemia (AML)

Lower DND1 mRNA levels
in AML blasts and CD34+
progenitor cells.

Inhibition of both RBM38 and DND1
mRNAs significantly attenuated NB4
differentiation and resulted in
decreased p21(CIP1) mRNA.

Activity of RBM38 and DND1
during neutrophil differentiation
antagonize the activity of oncomiRs
to protect mRNAs, for example
p21CIP1 that are important for
myeloid differentiation.

[16]

Skin cancer

Reduced expression of DND1
mRNA in transformed HaCaT
cells and loss of DND1 mRNA
and protein in tumors from
transformed HaCaT cells.

Expression of DND1 in transformed
HaCaT cells interfered with
miR-21-mediated repression of MSH2;
Knockdown of DND1 reduced MSH2
RNA, an effect further enhanced by
miR-21.

DND1, which decreases
sensitivity of MSH2 to miR-21,
is down-regulated during
tumorigenesis therefore
increasing the effectiveness
of miR-21 in tumors.

[15]

In a study on human breast cancer by Cheng et al., the group’s analysis of The Cancer
Genome Atlas (TCGA) microarray mRNA expression profiles for breast cancer found
that patients with higher DND1 levels had longer overall survival [17]. Furthermore,
comparison of 21 pairs of breast tumors and their neighboring mammary normal epithelial
tissues found two-fold lower DND1 mRNA levels in breast cancer tissues compared to
adjacent normal breast tissues. The lowest DND1 levels were detected in a panel of human
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breast cancer cell lines with highest metastatic capability. In addition, DND1 expression
was found to be positively correlated with the pro-apoptotic effector BIM expression in
human breast cancer. Experimentally, knockdown of DND1 in MCF-7 cells decreased BIM
expression and inhibited apoptosis. DND1 was found to increase BIM expression and
stability by blocking miR-221 from BIM-30 UTR.
Several studies also indicate that DND1 functions in GI cancers. In hepatocellular
carcinoma (HCC) cells, DND1 overexpression was found to inhibit spheroid formation,
suppress HCC cancer cell stemness, inhibit epithelial-mesenchymal transition and increase
the sensitivity of HCC cells to sorafenib [18]. The tumor-suppressive function of DND1
in HCC may at least partially result from Hippo signaling activation. It was shown that
through binding to LATS2 30 -UTR, DND1 overexpression led to elevated LATS2 level
and YAP phosphorylation and retention in the cytoplasm, diminishing the transcriptional
activity of the YAP oncogene.
In another study, mutant Dnd1Ter was found to significantly increase polyp number
and mass in the Apc+/Min mouse model of intestinal polyposis [14], indicating the tumorigenic properties of Dnd1Ter in the intestine. These above studies indicate that normal,
WT DND1 has tumor-suppressive type activity with increased DND1 expression being
anti-proliferative, pro-apoptotic, or causing reduction of cancer stemness. However, one
study contradicts this in that DND1 seems to play a tumor-promoting role in SW48 colorectal cancer cell line [19], as silencing DND1 suppressed cell proliferation and overexpression
of DND1 reversed the tumor-suppressive effects of miR-24.
In TSCC cells, DND1 itself was also identified as a target of miR-24 [13]. Downregulation of DND1 mediated by miR-24 led to reduced expression of cyclin-dependent
kinase inhibitor 1B (CDKN1B), whose translation is up-regulated by DND1. This was
accompanied by enhanced cell proliferation.
Lastly, DND1 seems to also play a role in non-solid tumors. The expression of DND1
and another RNA-binding protein RBM binding motif protein 38 (RBM38) is repressed
in primary acute myeloid leukemia patients [16]. Inhibition of DND1 and RBM38 mRNA
significantly attenuated differentiation of NB4 acute promyelocytic leukemia cells and
resulted in decreased p21(CIP1) mRNA expression.
In summary, different studies on DND1 function found that DND1 is an anti- proliferative, pro-apoptotic tumor suppressor in a variety of cancers, but may also exert oncogenic
function in others. The presence of different repertoires of mRNA/protein in different cells
or tissues may account for the opposite roles of DND1 detected in the cancer studies, as
DND1 stabilizes some mRNAs but suppresses or degrades others [7,9,10,29] (Figure 2),
and can also modify the activity of target protein [36]. Moreover, how DND1 functions
under different physiological conditions in the cell is unknown. It is also noteworthy that
the above-described studies in different cancer types each represent a single study and
further investigations are critically needed to verify these findings.
To complement the above-mentioned experimental studies on the role of DND1 in
somatic cancers, we queried the frequency of DND1 gene alteration in human cancers
from TCGA database. We examined data on liver, breast, skin, colon neoplasms and
AML in cBioPortal (cbioportal.org, accessed on 30 June 2021) [57,58]. DND1 gene shows
minimal alteration in these cancer types that we analyzed (data not shown), except that
it is altered, mostly through deletion, in 9.38% of melanomas. In addition, we found
high DND1 alteration frequency (>5%) in other three cancer types: lung (up to 18.75%),
prostate adenocarcinoma (up to 6.49%), and kidney renal clear cell carcinoma (up to
14.12%). Interestingly, while the majority of DND1 alteration is deletion or mutation in lung
and prostate cancers, DND1 amplification prevails in kidney cancers. It is imperative to
further explore the role of DND1 in these cancer types as to whether the changes in DND1
represent passenger events or whether DND1 directly contributes to cancer susceptibility
and progression.
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5. Genetically Engineered Mouse Alleles of DND1
In contrast to the cancer cell line studies and cancer genome data analysis, in vivo
model systems allow control of genetic background and testing of direct causal relationship,
and thus will serve as important tools for elucidating the possible roles of DND1 in somatic
cancers. In addition to the above-mentioned mice carrying the mutations of four aa residues
in RRM1 of DND1 (E59, V60, P76 and G82) [28], hereto, several genetically engineered
mouse alleles of Dnd1 have been generated by different laboratories to study germ cell
biology and germ cell cancers.
Two Dnd1 knockout mouse alleles generated by different research groups have reported to manifest different phenotypes and thus whether Ter simply causes DND1 loss
or produces a truncated DND1 protein remains controversial. The conventional Dnd1knockout mouse line, Dnd1∆ [31], was established by administering tamoxifen globally to
Dnd1+/flox ; Rosa26+/CreERT2 female mice [9]. These Dnd1∆ mice showed phenotypes similar
to those of Ter mutant mice in spermatogenesis, oogenesis, and teratoma incidence, with
a slight difference in spermiogenesis. The DND1 protein level in Dnd1+/Ter mice was half
of that in WT embryos and the expression of the shorter, truncated DND1 protein was
not detected. These data support that Ter mutation causes DND1 loss. However, another
study indicated that Dnd1Ter is not functionally equivalent to DND1 loss in mice [14]. This
Dnd1 knockout allele, Dnd1KO , caused embryonic lethality in Dnd1KO/KO homozygotes
and Dnd1+/KO heterozygotes were born with reduced numbers. Dnd1Ter only partially
rescued these phenotypes. In addition, while Dnd1+/KO heterozygous male mice did not
exhibit increased occurrence of TGCT, a single copy of Dnd1Ter was able to increase TGCT
risk regardless of whether the alternative allele was loss-of-function (Dnd1KO ) or WT. The
phenotypic discrepancy of the Dnd1∆ and Dnd1KO mice may at least be partially due to the
slight genetic difference between 129 substrains. In addition, the fact that different portions
of the Dnd1 gene were deleted in these two alleles may also account for the discrepancy. In
Dnd1∆ allele, exons 2-3 were removed, whereas exons 1–2 and most of exon 3 of Dnd1 were
deleted in the Dnd1KO allele. One cannot exclude the possibility that a truncated DND1 is
being produced from the Dnd1KO allele that retains partial DND1 function and could thus
reduce TGCT occurrence.
Mouse alleles that overexpress DND1 have also been generated. The LSL-FM-Dnd1flox
‘knock-in’ allele allows Cre recombinase-mediated expression of genetically engineered,
FLAG- and myc-tagged DND1 in a cell-type-specific manner [59]. The role of this allele in
cancer remains to be tested. The Dnd1-3XFLAG transgenic allele contains 3×FLAG-tag encoding sequence at the C-terminus of Dnd1, resulting in the expression of DND1-3×FLAG
fusion protein under the direct control of the Dnd1 enhancer [9]. As good antibodies for
co-immunoprecipitation experiments for DND1 are still unavailable, these alleles allow
pull down of DND1 binding partners with FLAG or myc antibodies. Furthermore, the
newly reported transgenic mouse line carrying a Dnd1GFP fusion allele enables in vivo
imaging of the DND1 protein and easy sorting of DND1 expressing cells [60].
Introduction of these DND1 deleted or overexpressing alleles into mouse models for
different cancer types will be highly informative to determine whether and how DND1
deletion or overexpression affects somatic cancers. These mouse alleles will undoubtedly
serve as valuable tools for addressing the role of DND1 in vivo and advance our knowledge
of DND1 function.
6. Conclusions and Future Perspective
Various studies have revealed and are still unravelling the molecular mechanisms of
DND1 function and its role in human cancer. Not surprisingly, DND1, as with many other
RNA-binding proteins, has multiple functions as demonstrated in the early embryo, germ
cells as well as in some mammalian somatic cells. DND1 has been found to regulate gene
translation through various mechanisms, including blocking miRNA access to target RNA
to stabilize the RNA, recruiting the CCR4-NOT complex to degrade the target RNA, and
activating preinitiation complex to promote translation initiation.
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Several questions remain unresolved in the rodent system, such as whether DND1Ter
is expressed and how and whether it acquires additional gain-of-function properties. In primordial germ cells of the mouse, WT DND1 interacts with germ cell-specific factors, for
example NANOS2 [9,30,31], to facilitate germ cell progression through rapidly changing
developmental states. As such, DND1 maintains cell viability while facilitating changes in
the pluripotency status and cell cycle states of germ cells. The exact mechanisms through
which DND1 functions to maintain viability of early germ cells is unclear. Defects in DND1,
such as Dnd1Ter mutation, lead to germ cell depletion and high TGCT incidences in genetically susceptible rodent strains where DND1Ter appears to function as a cancer modifier.
In addition to germ cell tumors, DND1 has been shown to be involved in some
somatic cancers. Thus far most experimental studies in somatic cancer cells indicate that
WT DND1 functions as a tumor suppressor with anti-proliferative and pro-apoptotic effects.
Cellular proteins that interact with DND1 to facilitate its function in somatic cells remain
to be discovered.
Human cancer database analysis revealed DND1 gene alterations in several different
cancer types. Whether DND1 is expressed ectopically in these cancers or induced due to
some stress response in cancer cells remains to be examined. Interestingly, in neuronal
cells, DND1 expression is turned on due to alcohol induced stress, most likely to facilitate
apoptosis [56,61]. Thus, we speculate that certain somatic cells may also retain the capacity
to induce DND1 in response to, for example, oncogenic stress. These ideas could be tested
experimentally using cell lines and animal models.
Compared with other extensively studied cancer-related genes, such as TP53, PTEN,
and KRAS, etc., the history of DND1 is still relatively short and its role in different cancers
is largely unknown. Key unanswered questions about DND1 include, but are not limited
to, what causes the 129-mouse strain-specific high TGCT incidences in Dnd1Ter mice, what
mechanisms steer the translation activating or suppressive role of DND1, and how DND1
functions in cancer cells. Understanding the myriad of DND1 functions, aided by animal
models, remains a critical avenue for future studies, as it is through these mechanisms
that we may come to understand cancer susceptibility factors to rationally design anticancer agents.
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